In the Daily Inter Lake, Thomas C. emphasizes that relying on Most Favored Nation (MFN) drug pricing models threatens future medical innovation and risks missing the root cause of systemic health care disparities. Rather than adopting overseas pricing schemes, Thomas advocates for policymakers to reform the federal 340B drug discount program and enforce real accountability for large hospital systems, specifically ensuring program discounts directly benefit true safety-net facilities, to deliver meaningful support to rural Montana patients.